These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 28177583

  • 1. Intralesional anti-CD20 antibody for low-grade primary cutaneous B-cell lymphoma: Adverse reactions correlate with favorable clinical outcome.
    Eberle FC, Holstein J, Scheu A, Fend F, Yazdi AS.
    J Dtsch Dermatol Ges; 2017 Mar; 15(3):319-323. PubMed ID: 28177583
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
    Kyrtsonis MC, Siakantaris MP, Kalpadakis C, Dimopoulou MN, Vassilakopoulos TP, Kontopidou FN, Antoniou C, Korkolopoulou P, Panayiotidis P, Pangalis GA.
    Eur J Haematol; 2006 Oct; 77(4):300-3. PubMed ID: 16856917
    [Abstract] [Full Text] [Related]

  • 6. Treatment of primary cutaneous B-cell lymphoma with rituximab.
    Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L.
    J Am Acad Dermatol; 2005 May; 52(5):847-53. PubMed ID: 15858476
    [Abstract] [Full Text] [Related]

  • 7. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G.
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab.
    Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH.
    J Am Acad Dermatol; 2008 Dec; 59(6):953-7. PubMed ID: 18817999
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.
    Fernández-Guarino M, Ortiz-Romero PL, Fernández-Misa R, Montalbán C.
    Actas Dermosifiliogr; 2014 Jun; 105(5):438-45. PubMed ID: 23540593
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intralesional rituximab for cutaneous B-cell lymphoma.
    Paul T, Radny P, Kröber SM, Paul A, Blaheta HJ, Garbe C.
    Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
    [Abstract] [Full Text] [Related]

  • 20. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.
    Heinzerling LM, Urbanek M, Funk JO, Peker S, Bleck O, Neuber K, Burg G, von Den Driesch P, Dummer R.
    Cancer; 2000 Oct 15; 89(8):1835-44. PubMed ID: 11042581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.